BioSpace News Archive

Valneva S E announced today that all the resolutions recommended by the Management Board were approved by the shareholders at its Annual General Meeting (AGM) held as a closed session at its registered office on June 23, 2021.

Milestone Scientific Inc. today announced that it has expanded its medical sales team including the appointment of Chet Trechock as VP of Sales Medical.

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming August 9, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired AcelRx Pharmaceuticals, Inc. (“AcelRx” or the “Company”) (NASDAQ: ACRX) securities between March 17, 2020 and February 12, 2021, inclusive (the “Class Period”).

GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced it will be making two poster presentations at two internationally-renown scientific and medical events in June 2021, including a thought-leadership documentary featuring Key Opinion Leaders (KOLs).

Arcus Biosciences, Inc. (NYSE:RCUS), today announced that, at the first interim analysis of the three-arm randomized Phase 2 ARC-7 study, both arms with domvanalimab-based combinations showed encouraging clinical activity (measured by overall response rate; ORR) when given as an initial treatment (first-line) to people with metastatic, PD-L1≥50% non-small cell lung cancer (NSCLC).

All of the ordinary shares in the offering are to be sold by Portage.

Paramit Corporation announced today that it has entered into a definitive agreement to be acquired by the Tecan Group (SIX Swiss Exchange: TECN) for a total purchase consideration of USD 1.0 billion (CHF 920 million)

Thermo Fisher Scientific, the world leader in serving science, today announced the launch of a new CE-IVD-marked COVID-19 test

Cipher Pharmaceuticals Inc. today announced the voting results for the election of directors at its Annual Meeting of Shareholders held earlier today.

Certara today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has renewed its licenses of Certara’s Simcyp™ and Phoenix™ biosimulation software.